NASDAQ:PMN Promis Neurosciences (PMN) Stock Price, News & Analysis $10.57 +0.13 (+1.24%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Promis Neurosciences Stock (NASDAQ:PMN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Promis Neurosciences alerts:Sign Up Key Stats Today's Range$10.50▼$10.8050-Day Range$9.83▼$23.7752-Week Range$6.27▼$39.75Volume6,359 shsAverage Volume125,894 shsMarket Capitalization$94.78 millionP/E RatioN/ADividend YieldN/APrice Target$26.50Consensus RatingHold Company Overview Promis Neurosciences, Inc. is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis. Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation. The company’s pipeline reflects a commitment to addressing unmet needs in neurology by optimizing compound profiles for safety, selectivity and central nervous system penetration. Promis Neurosciences collaborates with academic institutions and industry partners to accelerate its research and development efforts. These strategic alliances support biomarker identification, translational studies and clinical trial design, aiming to streamline candidate advancement and enrich patient selection strategies. The company is headquartered in the United States and its common stock trades on the Nasdaq stock exchange under the symbol PMN.AI Generated. May Contain Errors. Read More Promis Neurosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScorePMN MarketRank™: Promis Neurosciences scored higher than 52% of companies evaluated by MarketBeat, and ranked 510th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingPromis Neurosciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPromis Neurosciences has a consensus price target of $26.50, representing about 150.7% upside from its current price of $10.57.Amount of Analyst CoveragePromis Neurosciences has received no research coverage in the past 90 days.Read more about Promis Neurosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Promis Neurosciences is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Promis Neurosciences is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.60% of the float of Promis Neurosciences has been sold short.Short Interest Ratio / Days to CoverPromis Neurosciences has a short interest ratio ("days to cover") of 3.36, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Promis Neurosciences has recently increased by 2.29%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPromis Neurosciences does not currently pay a dividend.Dividend GrowthPromis Neurosciences does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News SentimentPromis Neurosciences has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Promis Neurosciences this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Promis Neurosciences to their MarketBeat watchlist in the last 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Cluster Insider Buying3 insiders have purchased shares of Promis Neurosciences in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $140,855.00 in company stock, which represents 0.1486% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Promis Neurosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $140,855.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders1.50% of the stock of Promis Neurosciences is held by insiders.Percentage Held by Institutions50.13% of the stock of Promis Neurosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Promis Neurosciences' insider trading history. Receive PMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Promis Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PMN Stock News HeadlinesProMIS Neurosciences Inc.: ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate HighlightsMay 12, 2026 | finanznachrichten.deProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate HighlightsMay 12, 2026 | globenewswire.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.May 19 at 1:00 AM | Banyan Hill Publishing (Ad)Insider Buying: Promis Neurosciences (NASDAQ:PMN) Director Buys 4,000 Shares of StockApril 24, 2026 | insidertrades.comProMIS Neurosciences (PMN) price target decreased by 57.76% to 35.06March 28, 2026 | msn.comProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate HighlightsMarch 25, 2026 | finanznachrichten.deProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate HighlightsMarch 25, 2026 | globenewswire.comProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)March 18, 2026 | globenewswire.comSee More Headlines PMN Stock Analysis - Frequently Asked Questions How have PMN shares performed this year? Promis Neurosciences' stock was trading at $6.8250 at the beginning of 2026. Since then, PMN shares have increased by 54.9% and is now trading at $10.5690. How were Promis Neurosciences' earnings last quarter? Promis Neurosciences (NASDAQ:PMN) announced its earnings results on Tuesday, May, 12th. The company reported ($1.26) EPS for the quarter, missing analysts' consensus estimates of ($1.06) by $0.20. When did Promis Neurosciences' stock split? Promis Neurosciences's stock reverse split on the morning of Friday, November 28th 2025.A 1-25 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Promis Neurosciences' major shareholders? Top institutional shareholders of Promis Neurosciences include Janus Henderson Group PLC (14.41%), Ally Bridge Group NY LLC (4.62%), Yu Fan (3.68%) and ADAR1 Capital Management LLC (1.06%). Insiders that own company stock include Abg Management Ltd, Eugene Williams, Madge K Shafmaster, Patrick D Kirwin, Johanne Kaplan, Max A Milbury and Neil Cashman. View institutional ownership trends. How do I buy shares of Promis Neurosciences? Shares of PMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Promis Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Promis Neurosciences investors own include PayPal (PYPL), Recursion Pharmaceuticals (RXRX), Pacific Biosciences of California (PACB), Editas Medicine (EDIT), Trimble (TRMB). Company Calendar Last Earnings5/12/2026Today5/19/2026AGM 20265/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 3 weeks, PMN's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PMN CIK1374339 Webwww.promisneurosciences.com Phone(416) 847-6898FaxN/AEmployees5Year Founded2001Price Target and Rating Average Price Target for Promis Neurosciences$26.50 High Price Target$35.00 Low Price Target$18.00 Potential Upside/Downside+150.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($14.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.72 million Net MarginsN/A Pretax MarginN/A Return on Equity-237.99% Return on Assets-151.04% Debt Debt-to-Equity RatioN/A Current Ratio9.92 Quick Ratio9.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.58) per share Price / Book-18.22Miscellaneous Outstanding Shares8,968,000Free Float8,833,000Market Cap$94.78 million OptionableNot Optionable Beta-0.20 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:PMN) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Promis Neurosciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Promis Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
